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Summary
Background Basophils are important effector cells involved in the pathogenesis of inflam-
matory skin diseases including chronic urticaria which is associated by increased IL-31
serum levels. So far the effects of IL-31 on human basophils are unknown.
Objective To analyse the functional role of IL-31 in basophil biology.
Methods IL-31 expression was evaluated in skin samples derived from chronic sponta-
neous urticaria patients. Oncostatin M receptor (OSMR), IL-31 receptor A (RA) and IL-31
protein expressions were analysed on human basophils from healthy donors. Basophil
responses to IL-31 were assessed for chemotaxis, externalization of CD63 and CD203c as
well as the release of histamine, IL-4 and IL-13.
Results IL-31RA and OSMR were expressed on human basophils. IL-31 was strongly
expressed in the skin of patients with chronic spontaneous urticaria and was released
from isolated basophils following either anti-IgE, IL-3 or fMLP stimulation. IL-31 induced
chemotaxis and the release of IL-4 and IL-13 which was specifically inhibited by anti-IL-
31RA and anti-OSMR. Conversely, IL-31 had no effect on CD63 and CD203c externaliza-
tion or histamine release.
Conclusions and Clinical Relevance Human basophils are a source of –and are activated
by – IL-31 with the release of pro-inflammatory cytokines and the induction of chemo-
taxis indicating an important novel function of IL-31 in basophil biology.
Keywords basophils, chemotaxis, chronic urticaria, histamine, IL-31
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Introduction
IL-31 plays an important role in inflammation and itch.
Increased levels of this cytokine have been shown in
inflammatory skin diseases including chronic sponta-
neous urticaria (CsU), atopic dermatitis, contact eczema
and in a subset of patients with mastocytosis [1–7]. In
atopic dermatitis, IL-31 levels correlate with disease
severity and increased Th2 cytokines, such as IL-4 and
IL-13, in serum and skin [2, 4, 5]. In a mouse model of
atopic dermatitis, anti-IL-31 treatment led to a signifi-
cant inhibition of scratching [8]. Furthermore, it has been
shown that the successful therapy of 15 patients with
CsU, which were excellent responders to omalizumab,
was associated with reduced IL-31 serum levels [9].
IL-31 signals via a heterodimeric receptor composed
of the IL-31 receptor A (IL-31RA) and the oncostatin M
receptor (OSMR). These IL-31 receptors are expressed
on several different cell types including T cells, ker-
atinocytes, dendritic cells, eosinophils, macrophages
and dorsal root ganglia [3, 10–14]. Expression of IL-31
has been described in mast cells of patients with psoria-
sis [15] and mastocytosis [6], in CD45RO+ CLA+ T cells
and in PBMCs of patients with atopic dermatitis [3, 16,
17] as well as eosinophils [13]. Functionally, IL-31 leads
to the release of pro-inflammatory cytokines in human
monocytes, macrophages and keratinocytes [12, 14].
This cytokine also regulates the differentiation and
expression of filaggrin in human organotypic skin
models [18].
Basophils have been recognized as important effector
cells in allergic reactions and in immune responses
against helminths [19]. These cells are highly mobile in
comparison with their mast cell counterparts and can
invade various tissues including the skin, lung and nose
([19, 20]. Inflammatory skin of chronic idiopathic
urticaria patients is also associated with increased num-
bers of basophils [21]. Basophils are capable of releas-
ing histamine, eicosanoids and several
immunomodulatory cytokines including IL-6 and IL-13.
Moreover, basophils are the prime early producers of
IL-4 which is rapidly released in large quantities from
these cells and is important for the early activation of T
cells. The effect of IL-31 on human basophils has not
yet been elucidated, and their ability to generate this
cytokine themselves has not been determined. As baso-
phils contribute to inflammatory skin diseases, our aim
was to investigate the role of IL-31 in these cells and to
discover whether basophils are a source of IL-31.
Methods
Isolation of basophils from peripheral blood
Human basophils were obtained from leucocyte concen-
trates (obtained by thrombopheresis) derived from
healthy blood donors and purified by magnetic cell
sorting (Stem Cell Technologies, Grenoble, France) as
previously described by us [22, 23]. The purity of iso-
lated basophils was 99–100% as assessed by alcian blue
staining and FACS analysis with antibodies against
CD123 (clone: 6H6, eBioscience, Frankfurt, Germany)
and FcƐR1a (clone: AER-37, eBioscience). All proce-
dures were approved by the local ethical committees of
the Hannover Medical School (approval number 5807)
and the University of Kent (NHS REC 12/WM/0319).
Basophils were cultivated in RPMI 1640 with 10%
heat-inactivated fetal calf serum (FCS) including 2 mM
L-glutamine, 10 000 U/mL penicillin and 10 mg/mL
streptomycin (all Seromed; Biochrom AG, Berlin,
Germany) at 37°C and 5% CO2.
Isolation of CD4+ T cells
CD4+ T cells were isolated from the same leucocytes that
were also used for basophil isolation. CD4+ T cells were
enriched using the CD4+ T cell Isolation Kit (Miltenyi Bio-
tec, Bergisch Gladbach, Germany). The purity of isolated
CD4+ T cells was 99–100% as assessed by FACS. In 96-
well plates, CD4+ T cells (1 9 105 per 100 lL) were incu-
bated in the same culture medium as described above for
basophils. CD4+ T cells were stimulated with purified NA/
LE mouse anti-human CD3 antibodies (1 lg/mL, clone:
HIT3a; BD Bioscience, Heidelberg, Germany) and purified
mouse anti-human CD28 antibodies (0.2 lg/mL, clone:
CD28.2, BD Bioscience).
IL-31 expression in skin samples
Paraffin-embedded lesional skin biopsies from patients
with CsU were analysed by double immunofluorescence
using the Vectastain kit (Vector Laboratories Inc., Bur-
lingame, CA, USA) as outlined before [6, 24]. Sections
(6 lm) were pre-treated for antigen retrieval and per-
meabilization (Vector Laboratories). Slides were then
incubated with either polyclonal rabbit anti-human IL-
31 (1 : 200; Abcam, Cambridge, UK) or rabbit IgG iso-
type control and subsequently stained with goat anti-
rabbit FITC (Jackson ImmunoResearch, West Grove, PA,
USA). Afterwards, monoclonal mouse anti-human 2D7
antibodies (2 lg/mL; Abcam) or respective mouse IgG1
isotype control (Jackson ImmunoResearch) was applied
with subsequent incubation with PE-conjugated goat
anti-mouse antibodies (Jackson ImmunoResearch). Sec-
tions were then incubated overnight at 4°C after which all
slides were examined using a Zeiss Axiocam with Axiovi-
sion software (Carl Zeiss, MicroImaging GmbH, G€ottin-
gen, Germany). Nuclei were stained with DAPI (Thermo
Fisher, Waltham, MA USA). The number of IL-31-positive
cells and IL-31-positive basophils in addition to IL-31
negative basophils was determined in nine different slides
of four different patients with CsU. Furthermore, we per-
formed phase contrasts of representative skin samples
(Zeiss Axiocam).
Western blot analysis
For IL-31 protein detection, a total of 1 9 106 baso-
phils were stimulated for 4 h and homogenized in M-
Per mammalian extraction reagent (Thermo Fisher).
SDS-PAGE using the extracted proteins was performed
on 4–20% gradient precise protein gels (Pierce, Thermo
Scientific). Proteins were then transferred to nitrocellu-
lose membranes and blocked with 5% non-fat dry milk.
Membranes were then sequentially incubated with poly-
clonal rabbit anti-human IL-31 (1 : 200; Abcam) fol-
lowed by a horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody (1 : 2000, Cell Signaling
Technology, Danvers, MA, USA). The blots were visual-
ized using a chemiluminescence kit according to the
manufacturer’s instructions (Pierce, Thermo Fisher) and
documented with Chemilmager 4400 (Biozym, Hess.
Oldendorf, Germany). Equal loading was assessed by
comparing with GAPDH expression using rabbit mono-
clonal anti-human GAPDH (14C10) antibodies (Cell Sig-
naling Technology). As a positive control, we used
100 ng/mL rhIL-31 (Peprotech, Rocky Hill, NJ, USA).
IL-31RA and OSMR expression
IL-31RA and OSMR expressions were analysed using
flow cytometry. Purified basophils (2 9 105) were
incubated with either APC-conjugated polyclonal goat
anti-human IL-31RA (0.5 lg/mL; R & D Systems,
Wiesbaden, Germany) or goat anti-human IgG isotype
control (R&D Systems). For the detection of OSMR, we
© 2016 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 1–10
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used PE-conjugated monoclonal mouse anti-human
OSMR (0.5 lg/mL, clone: An-V2, eBioscience) or mono-
clonal mouse anti-human IgG1 isotype control (R & D
Systems). Staining was performed for 1 h at 4°C, and
basophils were analysed using a FACS Calibur platform
(Becton Dickinson, San Jose, CA, USA).
Cytokine release
After 16 h in culture, purified basophils (2 9 105 per
200 lL) were stimulated for 30, 60 and 240 min with
anti-IgE (100 ng/mL, Sigma-Aldrich, Munich, Ger-
many), fMLP (1 lM, Sigma-Aldrich) or IL-31 (1 and
10 ng/mL). For blocking experiments, basophils were
stimulated with 10 lg/mL goat anti-human IL-31RA
(unconjugated; R & D Systems), 10 lg/mL mouse anti-
human OSMR (unconjugated; R & D System) or both
antibodies, or with a respective isotype control (normal
goat IgG and mouse IgG1, 10 lg/mL; R & D Systems)
before stimulation with IL-31 (10 ng/mL). Cytokine
release was determined for IL-4 (eBioscience, detection
limit: 2 pg/mL) and IL-13 (eBioscience, detection limit:
7.8 pg/mL) according to the manufacturer’s instructions
as previously described by us [22]. IL-31 release was
analysed from basophils stimulated with either anti-IgE,
fMLP, IL-3 (10 ng/mL, ImmunoTools, Friesoythe, Ger-
many) or buffer alone after 4 h incubation with a com-
mercial IL-31 ELISA (Blue Gene, detection limit: 2.5 pg/
mL) as previously described [6]. All experiments were
conducted in duplicate for each basophil donor
employed; analysis was performed using the FLUOStar
Optima plate reader (BMG Labtechnologies, Offenburg,
Germany).
Externalization of CD63 and CD203c
Heparinized human whole blood was incubated for
20 min with or without IL-31 (10 ng/mL) and subse-
quent stimulation with anti-IgE (100 ng/mL) and fMLP
(1 lM) for a further 20 min. Externalization of the baso-
phil activation marker CD63 (FITC-conjugated mono-
clonal mouse anti-human CD63 antibodies, clone:
H5C6) was measured using a commercially available
basophil activation test (BAT, Orpegen Pharma, Heidel-
berg, Germany) as outlined before [25].
Expression of CD203c was analysed using PE-conju-
gated monoclonal mouse anti-human antibodies (clone:
NP4D6; eBioscience). The samples were prepared and
stained using the aforementioned basophil activation
kit under the same conditions.
Histamine release
Purified basophils (2 9 105 cells) were resuspended in
HEPES-buffered Tyrode’s solution (400 lL per tube)
containing 1 mM CaCl2, placed in a water bath
warmed to 37°C and incubated with either IL-3, IL-
31, IL-33 (each at 10 ng/mL) or buffer alone. After
15 min, basophils were stimulated with anti-IgE
(100 ng/mL, Sigma-Aldrich, goat affinity-isolated anti-
body) or buffer alone. Reactions were allowed to pro-
ceed for 30 min for the analysis of histamine release.
Reactions in the latter case were terminated by add-
ing ice-cold calcium-free HEPES buffer followed by
centrifugation and immediate transfer of supernatants
into new vials. Histamine contents in the super-
natants, together with the cell pellets, which were
diluted accordingly and lysed with perchloric acid
(4%) were measured spectrofluorometrically. Histamine
release was determined from the total histamine con-
tent in the sum of pellet and supernatant as outlined
before [26].
Chemotaxis
Chemotactic activity was assessed using modified
Boyden chambers, which contained either IL-31
(10 ng/mL) or fMLP (1 lM, used as positive control)
or medium alone (baseline) and were covered with
polycarbonate filters (pore size 3 lm). Basophil sus-
pensions (5 9 105 per 100 lL) were then added on
top of these filters for each chamber. After incubation
for 3 h at 37°C, basophils, which migrated to the
lower part of the Boyden chambers, were lysed by
adding 0.1% Triton X-100. ß-Glucuronidase activity
in the lysates was determined photometrically using
p-nitrophenyl ß-glucuronide as a substrate. Values
were calculated by a computer-assisted technique
from a standard curve using known numbers of
unchallenged basophils. Chemotactic activity was pre-
sented as a chemotactic index with the ratio of the
number of migrated cells in the presence of stimulus
to the number of migrated cells in the presence of
medium alone.
Statistical analysis
All data are presented as box-and-whisker plot with
minimum and maximum, if not otherwise stated.
Statistical analysis was performed with GraphPad
Prism 5. Data, which passed the normality test, were
analysed with either a Student’s t-test or by a one-
way ANOVA followed by a Tukey post-test. If the data
did not follow a Gaussian bell-shaped distribution
for more than two groups of data, the Kruskal–Wal-
lis test or the Friedmann test followed by Dunn’s
post-test was used. Additionally, a two-way ANOVA
followed by a Bonferroni post-test was performed. A
P-value of < 0.05 was considered to be statistically
significant.
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Results
Basophils in chronic urticaria skin lesions are IL-31-
positive
CsU is characterized by increased IL-31 serum levels
[7]. Further, CsU lesions display an infiltration of baso-
phils [27]. Thus, we analysed whether basophils could
also be a source of IL-31 in skin samples of patients
with CsU using immunofluorescence. We were able to
detect IL-31-expressing basophils (2D7/IL-31, yellow)
alongside other IL-31-producing cells (green) (Fig. 1a-c).
To show the anatomical location of IL-31-positive
basophils, we performed phase contrast imaging
(Fig. 1d) together with respective double staining by
immunofluorescence (Fig. 1e). Finally, we analysed the
number of IL-31-expressing basophils using nine slides
from four different patients with CsU (Fig. 1f). We
observed that almost all basophils in the skin were
also positive for IL-31 and that the majority of IL-31-
expressing cells were basophils. In contrast, healthy
donor skin samples showed no IL-31-positive basophils
(isotype controls were also negative; data not shown).
Basophils express and release IL-31
The in vivo findings led us to investigate the role of IL-31
in basophils in more detail. Hence, we incubated purified
basophils from healthy donors for 4 h with either anti-
IgE, fMLP, IL-3 or IL-3 in combination with anti-IgE and
performed Western blotting for IL-31 expression.
Stimulation with anti-IgE and fMLP increased IL-31
expression compared to unstimulated basophils (Fig. 2a).
IL-3 alone had no significant effect and did not increase
IgE-dependent IL-31 protein expression (Fig. 2a). Using
cell lysates of stimulated basophils, we could see a signif-
icant increase in IL-31 expression by ELISA after stimu-
lation with fMLP compared to unstimulated basophils
(Fig. 2b). Next, we analysed basophil supernatants by
ELISA and again observed a significant increase in IL-31
release from basophils stimulated with fMLP compared to
unstimulated basophils (Fig. 2c).
T cells – especially of the CLA+ subtype – release
increased levels of IL-31 after 24 h [3]. Thus, we
wanted to assess whether basophils express similar
levels of IL-31 compared to T cells in vitro. For this
purpose, we isolated basophils and CD4+ T cells from
the same donors. The cells were cultivated for 24 h and
then stimulated for 4 h with either fMLP or the T cell-
specific stimulus CD3/CD28. We could confirm our
previous finding with respect to IL-31 release after
stimulation with fMLP in basophils (Fig. 2d). The T cell-
specific stimulus CD3/CD28 also led to a significant
release of IL-31 in CD4+ T cells (Fig. 2d). Comparing
both cell types, basophils displayed a significantly
higher release of IL-31 than CD4+ T cells (Fig. 2d).
Basophils express IL-31 receptors
IL-31 activates the signal cascade through its interaction
with a heterodimeric receptor composed of IL-31RA and







2D7 with phase contrast 2D7/IL-31 
Fig. 1. IL-31 expression in basophils from patients with CsU. Double immunofluorescence staining for IL-31 and basophils in paraffin sections
from CsU skin lesions. Staining was performed with antibodies against human basophils (a, c, d, e, 2D7, red) and IL-31 (b, c, e, green). Arrows
point to IL-31-positive basophils displayed as yellow in the overlay. Asterisks mark IL-31-positive cells other than basophils. Nuclei were stained
with DAPI (blue). (f) Quantification of 2D7/IL-31-positive and single-stained cells from sections of patients with CsU (n = 4 patients with nine
slides each displayed as scatter dot blot with mean  SEM).
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expression in isolated basophils from healthy donors by
flow cytometry. Initially, to avoid possible contamina-
tion, the isolated cell population was analysed for FceR1a
and CD123 expressions to verify the purity of our baso-
phil population (Fig. 2e, upper panel). Only FceR1a+/
CD123+-expressing cells were then analysed for IL-31RA
and OSMR expressions. While nearly all basophils were
IL-31RA-positive, only a small subpopulation of baso-
phils were positive for OSMR (Fig. 2e, lower panels).
OSMR/IL-31RA double staining of basophils showed that
almost all OSMR-positive basophils were also positive for
IL-31RA (Fig. 2f).
IL-31 induces the release of cytokines
IL-31 is known for its functional effects on the secre-
tion of pro-inflammatory cytokines of several immune
cells. Thus, we stimulated purified basophils with IL-
Fig. 2. Expression of IL-31, IL-31RA and OSMR on human basophils. Human basophils from healthy donors were isolated as described in material
and methods (Co: unstimulated basophils, **P < 0.01, ***P < 0.001). (a) Detection of IL-31 was performed from protein lysates by Western blot
(WB). Basophils were stimulated for 4 h with anti-IgE (a-IgE, 100 ng/mL), fMLP (1 lM) and IL-3 (10 ng/mL) alone or combined with a-IgE. (One
representative WB is shown out of four; M: ladder; Co: unstimulated basophils.) GAPDH was used as a reference protein. As control, rh IL-31 was
used. (b) Determination of IL-31 protein in cell lysates employed for WB using ELISA (n = 4). (c) IL-31 release of the corresponding supernatants
from the same basophils employed for WB using ELISA (n = 4). (d) Determination of IL-31 in the supernatants of isolated basophils and CD4+ T
cells (1 9 105 cells per 100 lL from the same donors; n = 7 different donors) cultivated for 24 h and then stimulated with either fMLP or CD3/
CD28 (CD3: 1 lg/mL; CD28: 0.2 lg/mL) for 4 h. (e) Purity of freshly isolated basophils determined by FACS analysis using antibodies against
FcƐR1a and CD123 (one representative scatter dot blot out of five); receptor staining of IL-31RA and OSMR on freshly isolated basophils from
healthy donors analysed by FACS displayed as a histogram (one representative shown out of five). (f) One representative scatter dot plot of human
basophils stained for IL-31RA and OSMR (n = 5) and quantification of IL-31RA and OSMR double-positive basophils (n = 5).
© 2016 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 1–10
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31 (10 ng/mL) for 4 h to assess cytokine release. The
secretion of IL-4 and IL-13 was significantly
increased after stimulation with IL-31 in comparison
with unstimulated basophils (Fig. 3a, c), although
levels were not as high as IL-4 and IL-13 release fol-
lowing IgE-dependent stimulation (Fig. 3a, c). In addi-
tion, we also analysed the kinetics of IL-4 and IL-13
secretions from basophils stimulated with two concen-
trations of IL-31 (1 and 10 ng/mL). IL-4 release and IL-
13 release were rapidly and significantly increased in IL-
31-stimulated basophils compared to those with no
stimulation (Fig. 3b, d). Interestingly, we observed signif-
icant release of IL-4 and IL-13 with a concentration of
1 ng/mL IL-31 after 4 h of stimulation (Fig. 3b, d). With
a concentration of 10 ng/mL IL-31, IL-4 secretion was
significantly increased after 240 min (Fig. 3b) and IL-13
secretion was significantly increased after 60 and
240 min of stimulation (Fig. 3d). To verify the specificity
of these responses, we compared stimulated basophils
with those co-incubated with IL-31 antibodies which
block IL-31RA and OSMR. These blocking antibodies sig-
nificantly inhibited IL-13 release in IL-31-stimulated
Fig. 3. IL-31 stimulation induces IL-4 and IL-13 secretion. Human basophils from healthy donors were stimulated with IL-31 (10 ng/mL) or anti-
IgE (a-IgE, 100 ng/mL). (Co: unstimulated basophils, *P < 0.05, **P < 0.01, ***P < 0.001). (a) Secretion of IL-4 from purified basophils was mea-
sured by ELISA after 4 h of stimulation (Co and IL-31: n = 21; a-IgE: n = 10). (b) Kinetics of IL-4 secretion. Purified human basophils from
healthy donors were measured by ELISA after 30, 60 and 240 min stimulation with 1 and 10 ng/mL IL-31 (Co: unstimulated basophils; (30 min:
n = 6; 60 min: n = 10; 240 min: n = 21;). (c) Secretion of IL-13 from purified basophils as measured by ELISA after 4 h of stimulation (Co and
IL-31: n = 16; a-IgE: n = 5). (d) Kinetics of IL-13 secretion. Purified human basophils from healthy donors were measured by ELISA after 30, 60
and 240 min stimulation with 1 and 10 ng/mL IL-31 (Co: unstimulated basophils; (30 min: n = 4; 60 min: n = 10; 240 min: n = 16). (e) Determi-
nation of IL-13 release after stimulation with IL-31 for 4 h and co-incubation with either anti-IL-31 RA (a-IL-31RA) or anti-OSMR (a-OSMR) or a
combination of both antibodies. As controls, the respective isotype antibodies were used (n = 4).
© 2016 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 1–10
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basophils (Fig. 3e). Similar observations were made
regarding IL-4 release (data not shown). The isotype con-
trols for the IL-31RA and OSMR had no effect on IL-31-
stimulated basophils and led to IL-13 release as seen with
IL-31 stimulation alone (Fig. 3e).
IL-31 does not affect CD63 and CD203c externalization
or histamine release
As cytokines or hormones can affect the degranulation
of basophils [28, 29], we wondered whether IL-31 has
an impact on the externalization of CD203c and CD63.
For this, basophils were stimulated with either anti-IgE,
fMLP or IL-31, or costimulated with IL-31 and anti-IgE.
Surprisingly, IL-31 stimulation did not increase the
externalization of CD63 (Fig. 4a) and CD203c (Fig. 4b)
in comparison with unstimulated basophils. Addition-
ally, incubation with IL-31 did not affect histamine
release and did not enhance it in conjunction with anti-
IgE stimulation (Fig. 4c). In contrast, IL-3 and IL-33,
which are known primers for enhanced IgE-dependent
histamine release, caused substantial potentiation of
anti-IgE-induced histamine release in the same settings
(Fig. 4c).
IL-31 induces basophil migration
To investigate whether IL-31 induces chemotaxis, a
mechanism playing an important role in the accumula-
tion of basophils at sites of inflammation, we performed
a modified Boyden chamber assay. We observed a clear
induction of chemotaxis after stimulation with 10 ng/
mL IL-31 (Fig. 4d). FMLP was used as positive control
and induced chemotaxis as expected (Fig. 4d).
Discussion
Our study demonstrates for the first time that human
basophils express IL-31 receptors and are a source of
IL-31 in vitro and in vivo. Furthermore, we show novel
data regarding the functional effects of IL-31 on human
basophils including the induction of chemotaxis and
release of pro-inflammatory cytokines (IL-4 and IL-13).
Surprisingly, however, basophil histamine release and
externalization of CD63 as well as CD203c were not
affected by IL-31 exposure.
Mast cells, which share many common phenotypic
features with basophils, express IL-31 when stimulated
with antimicrobial peptides or in diseases such as
Fig. 4. IL-31 induces chemotaxis but not CD63/CD203c externalization or histamine release. (a–c) Basophil activation test (BAT): Externalization
of CD63 (a) and CD203c (b) on basophils stimulated with IL-31 (10 ng/mL), fMLP and anti-IgE (a-IgE, 100 ng/mL) or a combination of IL-31/anti-
IgE (Co: control; n = 11; MFI: mean fluorescence intensity; *P < 0.05; ***P < 0.001). (c) Effect of IL-31 (10 ng/mL) on histamine release from
purified basophils in comparison with IL-3 (10 ng/mL) and IL-33 (10 ng/mL) (used as positive control) either alone or in conjunction with anti-
IgE (a-IgE, 100 ng/mL). (Co: control; n = 5 separate donors; *P < 0.05, ***P < 0.001). (d) Migration of freshly isolated basophils in the presence
of IL-31 (10 ng/mL) was investigated in a modified Boyden chamber. fMLP (1 lM) was used as a positive control. Chemotactic activity is presented
as the ratio of the number of migrated basophils in the presence of stimulus/migrated basophils in the presence of the medium (*P < 0.05; n = 5
separate donors).
© 2016 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 1–10
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myeloproliferative disorders [15, 30]. Additionally, it
was shown that mast cells express the IL-31 receptor
[31]. In this context, it is interesting that atopic der-
matitis mouse models show high IL-31 concentrations
in addition to an increased number of mast cells in the
skin [1, 32]. Until now, the effect of IL-31 on basophils
and mast cells and the function of IL-31-expressing
basophils and mast cells in vivo have not been investi-
gated. In our study, we could show that IL-31 induced
basophil chemotaxis and induced the secretion of IL-4
and IL-13 from these cells. This suggests that IL-31 par-
ticipates in orchestrating and enhancing pro-allergic
immune responses, because the induction of IL-4
release may favour the subsequent differentiation of
Th0-CD4+ T cells to a Th2 phenotype. Indeed, it has
been shown that CsU is associated with increased IL-4
serum levels [33]. In this context, it is interesting to
note that IL-31 serum levels are higher in CsU patients
compared to healthy donors [7]. It is thus tempting to
speculate that increased serum IL-31 is the key mecha-
nism for increased IL-4 serum levels in these patients.
However, further experiments are needed to clarify this.
It was shown that IL-31 expression by Th1 cell clones
depends on the presence of IL-4, suggesting the regula-
tion of IL-31 tissue levels to be an additional
immunomodulatory function of basophils supplemental
to their regulation of T cell differentiation [34].
The functional interactions are likely to be mediated
via expression of the IL-31 receptor complex consisting
of IL-31RA and OSMR in basophils, which was shown
for other types of granulocytes including eosinophils,
which are derived from similar stem cells as basophils
[13, 35]. Interestingly, surface expression of IL-31RA
was significantly higher than OSMR but all basophils
positive for OSMR were also positive for IL-31RA. The
functional activity seems to depend on the expression
of both the OSMR and IL-31RA because we show here
that blocking of one or the other receptor decreases
IL-4 and IL-13 release in IL-31-stimulated basophils.
Stimulation of basophils with IL-31 clearly led to the
release of IL-4 and IL-13. This is interesting, given the
fact that children with atopic dermatitis display
increased IL-31 serum levels and a positive correlation
between IL-31 and IL-4 and IL-13 levels with disease
severity [4, 5]. Another interesting function of IL-31 is
its involvement in filaggrin expression [18]. Atopic der-
matitis is mostly characterized by filaggrin deficiency,
whereas in chronic urticaria, filaggrin expression has
been reported to be enhanced [36]. As IL-31 serum
levels are higher in atopic dermatitis compared to CsU
[7], it may be possible that regulation of filaggrin
expression is dependent on IL-31 serum levels.
The surface marker CD203c, an ecto-nucleotide
pyrophosphatase/phosphodiesterase, is specifically
expressed on basophils and mast cells. We did not
observe an externalization of CD203c in basophils stim-
ulated with IL-31. Additionally, IL-31 failed to increase
the externalization of CD63 and did not affect basophil
histamine release. Histamine release from anaphylactic
degranulation is accompanied by increased externaliza-
tion of CD63, whereas an upregulation of CD203c alone
could indicate piecemeal degranulation in basophils
[37]. However, as IL-31 caused the secretion of IL-4
and IL-13 from basophils without affecting both CD63
or CD203c externalization (and subsequent histamine
release), this demonstrates a unique mechanism of
action compared to other known basophil activators.
Our results clearly demonstrate that basophils are a
source of IL-31 themselves. We detected IL-31 in the
supernatants of basophil cultures using ELISA, Western
blot analysis and cell lysates where IL-31 concentra-
tions were increased after stimulation. Given the fact
that IL-31 orchestrates several pro-inflammatory func-
tions in various other immune cells, including T cells,
this further underlines the potential immunomodulatory
function on basophils.
In CsU skin lesions, increased numbers of basophils
have been detected [27]. Furthermore, IL-31 serum
levels are increased in patients with CsU [7]. Also, in a
study of 15 excellent responders to omalizumab, suc-
cessful treatment of these patients not only improved
clinical symptoms but was associated with reduced
IL-31 serum levels [9]. In this regard, the striking IL-31
release in vitro suggests that basophils are an important
source of IL-31 in the inflammatory response. Further-
more, our in vitro findings of increased chemotaxis
induced by IL-31 in basophils indicate a role in the
orchestration and accumulation of these cells in
inflamed skin such as in urticaria. Indeed, we could
show here that basophils are positive for IL-31 in skin
lesions of CsU patients. In other chronic inflammatory
skin diseases, IL-31-positive mast cells have been
described in psoriasis and in mastocytosis and for CLA+
T cells in atopic dermatitis and infiltrating T cells [3, 6,
14, 15]. Thus, it seems that local expression of IL-31 is
predominantly regulated by immune cells including
basophils, underlining a novel modality of basophils in
orchestrating the inflammatory response.
In conclusion, IL-31 stimulates a pro-inflammatory
activation pattern in human basophils which are a
source of IL-31 themselves. Thus, IL-31 therefore is a
potential target for novel therapeutic treatment strate-
gies in basophil-associated inflammatory diseases.
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